HCPCS Level II code J9218 denotes leuprolide acetate billed per 1 mg unit, an injectable GnRH agonist widely used in oncology, gynecology, and endocrinology. Nationally, accurate coding for J9218 matters because it drives drug reimbursement, impacts clinical cost management in outpatient infusion and ambulatory settings, and informs utilization monitoring for high-cost specialty pharmaceuticals. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9218 represents clinically and operationally, payer coverage considerations, common modifiers associated with injectable drug billing (listed separately), and the contexts in which J9218 is typically billed. The publication also outlines benchmark topics and policy considerations relevant to specialty injectable drugs, including unit-based billing implications and site-of-service distinctions. Data gaps in the input are noted where specific payer policies, ICD-10 pairings, and taxonomy mappings are not provided. This summary is intended to inform billing managers, revenue cycle professionals, and clinical leaders about the billing identity and typical use cases for HCPCS Level II code J9218.